Masimo Corporation $MASI Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. cut its position in Masimo Corporation (NASDAQ:MASI) by 15.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 397,248 shares of the medical equipment provider’s stock after selling 73,793 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Masimo were worth $58,614,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Royal Bank of Canada boosted its position in shares of Masimo by 44.5% during the first quarter. Royal Bank of Canada now owns 43,884 shares of the medical equipment provider’s stock worth $7,311,000 after buying an additional 13,513 shares during the period. AQR Capital Management LLC increased its holdings in shares of Masimo by 136.5% during the first quarter. AQR Capital Management LLC now owns 8,142 shares of the medical equipment provider’s stock valued at $1,305,000 after purchasing an additional 4,700 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Masimo by 0.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,371 shares of the medical equipment provider’s stock valued at $1,894,000 after purchasing an additional 66 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Masimo during the first quarter valued at about $220,000. Finally, Jones Financial Companies Lllp lifted its holdings in Masimo by 1,267.1% in the first quarter. Jones Financial Companies Lllp now owns 2,201 shares of the medical equipment provider’s stock worth $367,000 after purchasing an additional 2,040 shares during the period. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Price Performance

MASI stock opened at $139.87 on Friday. Masimo Corporation has a one year low of $125.94 and a one year high of $194.88. The firm has a 50-day moving average of $139.28 and a two-hundred day moving average of $146.45. The firm has a market capitalization of $7.51 billion, a PE ratio of -13.27, a P/E/G ratio of 1.41 and a beta of 1.26. The company has a current ratio of 2.84, a quick ratio of 1.92 and a debt-to-equity ratio of 0.69.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, November 4th. The medical equipment provider reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.12. The business had revenue of $371.20 million for the quarter, compared to the consensus estimate of $366.89 million. Masimo had a negative net margin of 33.20% and a positive return on equity of 33.04%. The firm’s quarterly revenue was up 8.2% compared to the same quarter last year. During the same period last year, the firm posted $0.86 earnings per share. Masimo has set its FY 2025 guidance at 5.620-5.790 EPS. On average, analysts forecast that Masimo Corporation will post 4.1 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on MASI. Bank of America assumed coverage on shares of Masimo in a research report on Monday, November 17th. They set a “neutral” rating and a $162.00 price target on the stock. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research report on Monday, December 1st. Wells Fargo & Company reissued an “overweight” rating and issued a $190.00 price objective on shares of Masimo in a research note on Friday, December 5th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Masimo in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Masimo from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Masimo presently has a consensus rating of “Hold” and a consensus price target of $189.40.

Masimo Company Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.